HomeTechnologyICMR to advance 1st-in-human trials for Zika, flu vax, blood cancers with...

ICMR to advance 1st-in-human trials for Zika, flu vax, blood cancers with industry partners

New Delhi, Sep 14 (IANS) In a significant move to strengthen India’s clinical research ecosystem, the Indian Council of Medical Research (ICMR) on Saturday announced that it has partnered with industry and academics to advance first-in-human clinical trials for vaccine against Zika and seasonal flu and therapies for blood cancers.

“The initiative is a crucial step towards establishing India as a leader in the clinical development of pharmaceutical agents,” said the Ministry of Health and Family Welfare.

Under its network of Phase 1 clinical trials, ICMR said it has formalised a Memorandum of Agreements (MoAs) with multiple sponsors for four promising molecules.

As per the agreements, the ICMR will undertake collaborative research over a small molecule for multiple myeloma (a blood cancer that affects the plasma cells) with Bengaluru-based Aurigene Oncology.

The apex research body has partnered with Indian Immunologicals, based in Hyderabad, for the development of a Zika vaccine. It has coordinated with Mynvax Private, based in Bengaluru for a trial of a vaccine against the seasonal Influenza virus.

The ICMR has also signed a pact with Navi Mumbai-based ImmunoACT to conduct a CAR-T cell therapy advancement study for a new indication of chronic lymphocytic leukemia (a type of cancer of the blood and bone marrow).

“The initiative positions India to emerge as a global leader in healthcare innovation. It is a key milestone in the pursuit of affordable and accessible cutting-edge treatments for all citizens,” said Union Health and Family Welfare Minister J P Nadda.

“Establishing Phase 1 clinical trial infrastructure is a key component in fostering the development of indigenous molecules and cutting-edge treatments. Our vision is to expand this network further, ensuring that India continues to lead in the development of innovative and affordable healthcare solutions,” added Dr. Rajiv Bahl, Secretary, Department of Health Research and Director General, ICMR.

The ICMR Network for Phase 1 Clinical Trials comprises four strategically located institutions across India — KEMH and GSMC, Mumbai; ACTREC, Navi Mumbai; SRM MCH and RC, Kattankulathur; and PGIMER, Chandigarh — supported by a Central coordinating unit at ICMR Headquarters in New Delhi.

–IANS

rvt/

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular